Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

(2021) Milind M. Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting FGFR inhibition in cholangiocarcinoma

(2021) Lipika Goyal et al.   CANCER TREATMENT REVIEWS

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

(2021) Alessandro Rizzo et al.   Cancers

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

(2021) Milind Javle et al.   Lancet Gastroenterology & Hepatology

The Landmark Series: Intrahepatic Cholangiocarcinoma

(2020) Jordan M. Cloyd et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular targeted therapies: Ready for “prime time” in biliary tract cancer

(2020) Angela Lamarca et al.   JOURNAL OF HEPATOLOGY

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

(2020) Richard D. Kim et al.   JAMA Oncology

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

(2020) Changhoon Yoo et al.   Journal for ImmunoTherapy of Cancer

Cholangiocarcinoma: investigations into pathway-targeted therapies

(2020) Ioannis Ntanasis-Stathopoulos et al.   Expert Review of Anticancer Therapy

Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma

(2020) Diamantis I. Tsilimigras et al.   JAMA Surgery

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm

(2020) Sakti Chakrabarti et al.   Cancers

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

(2019) Tatsuya Ioka et al.   JOURNAL OF CLINICAL ONCOLOGY

O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial

(2019) J Harding et al.   ANNALS OF ONCOLOGY

Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection

(2019) Fabio Bagante et al.   SURGERY

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

(2019) Makoto Ueno et al.   Lancet Gastroenterology & Hepatology

A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients

(2019) Diamantis I. Tsilimigras et al.   ANNALS OF SURGICAL ONCOLOGY

Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma

(2019) Sylvie Job et al.   HEPATOLOGY

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma

(2018) Benjamin Goeppert et al.   BRITISH JOURNAL OF CANCER

PD-L1 expression in extrahepatic cholangiocarcinoma

(2017) Dirk Walter et al.   HISTOPATHOLOGY

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma

(2017) Jacqueline Fontugne et al.   Oncotarget

Epidemiology and risk factors: intrahepatic cholangiocarcinoma

(2017) Amar Gupta et al.   HEPATOBILIARY SURGERY AND NUTRITION

Biliary cancer: Utility of next-generation sequencing for clinical management

(2016) Milind Javle et al.   CANCER

Intrahepatic Cholangiocarcinoma: expert consensus statement

(2015) Sharon M. Weber et al.   HPB

Molecular mechanism of cholangiocarcinoma carcinogenesis

(2014) Kosei Maemura et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

(2014) Supriya K. Saha et al.   NATURE

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

Multidisciplinary approaches to intrahepatic cholangiocarcinoma

(2013) Shishir K. Maithel et al.   CANCER

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

(2013) Daniela Sia et al.   GASTROENTEROLOGY

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome

(2013) Scott Robertson et al.   HUMAN PATHOLOGY

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

(2013) D Sia et al.   ONCOGENE

Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks

(2013) J. P. Wagner et al.   Science Signaling

Recurrence after operative management of intrahepatic cholangiocarcinoma

(2013) Omar Hyder et al.   SURGERY

Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma

(2012) Naoki Oishi et al.   HEPATOLOGY

Different roles of S100P Overexpression in Intrahepatic Cholangiocarcinoma

(2011) Shinichi Aishima et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

STAT3 SIGNALING: Anticancer Strategies and Challenges

(2011) P. A. Johnston et al.   MOLECULAR INTERVENTIONS

Clinical diagnosis and staging of cholangiocarcinoma

(2011) Boris Blechacz et al.   Nature Reviews Gastroenterology & Hepatology

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors

(2010) Vincenzo Cardinale   World Journal of Gastrointestinal Oncology

Intrahepatic Cholangiocarcinoma

(2009) Itaru Endo et al.   ANNALS OF SURGERY

The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival

(2009) Sae-Byeol Choi et al.   ANNALS OF SURGICAL ONCOLOGY

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

(2008) S.A. Khan et al.   HPB